In contrast, our findings align with a nationwide observational registry study by H. Christian Rosén, which demonstrated a significant reduction in mortality with SGLT2 inhibitors in patients with T2DM following an AMI [44]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.